Kena A. Swanson, Ph.D.

Vice President, Viral Vaccines
Pfizer

Disclosure(s): Pfizer: Employee of Pfizer, Stocks/Bonds (Public Company)

Poster(s):

• (P-595) Public Health Impact of RSVpreF Vaccination on Older Adult Disease Outcomes
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-596) Immunobridging Demonstrating Effectiveness of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Adults 18-59 Years of Age at High Risk of Severe RSV Disease in a Phase 3 Trial: The C3671023 MONeT Study Results
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-600) Efficacy of a Bivalent RSVpreF Vaccine in Older Adults Across a Second RSV Season
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-605) Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High and Durable Neutralizing Titers Across an Entire RSV Season among Older Adults
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT